MX2022002062A - Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii. - Google Patents

Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii.

Info

Publication number
MX2022002062A
MX2022002062A MX2022002062A MX2022002062A MX2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A
Authority
MX
Mexico
Prior art keywords
kinases
diseases
pyrazole
inhibitors
pdgfr
Prior art date
Application number
MX2022002062A
Other languages
English (en)
Spanish (es)
Inventor
Shao-Zheng Peng
Chu-Bin Liao
Hung-Jyun Huang
Yuan-Ting Cho
Yi-Mei Chang
Yu-Chih Pan
Original Assignee
Dev Ct Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Ct Biotechnology filed Critical Dev Ct Biotechnology
Publication of MX2022002062A publication Critical patent/MX2022002062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2022002062A 2019-08-23 2020-08-22 Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii. MX2022002062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2022002062A true MX2022002062A (es) 2022-04-25

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002062A MX2022002062A (es) 2019-08-23 2020-08-22 Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii.

Country Status (11)

Country Link
US (1) US12448394B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017853A4 (cg-RX-API-DMAC7.html)
JP (1) JP7651557B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051365A (cg-RX-API-DMAC7.html)
CN (1) CN114502553B (cg-RX-API-DMAC7.html)
AU (1) AU2020337883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002062A (cg-RX-API-DMAC7.html)
TW (1) TWI759829B (cg-RX-API-DMAC7.html)
WO (1) WO2021041276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
BRPI0618011A2 (pt) * 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
WO2013142382A1 (en) * 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US8853207B2 (en) * 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物

Also Published As

Publication number Publication date
CN114502553A (zh) 2022-05-13
AU2020337883B2 (en) 2025-08-28
WO2021041276A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
US12448394B2 (en) 2025-10-21
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
CN114502553B (zh) 2024-07-26
TW202115087A (zh) 2021-04-16
EP4017853A1 (en) 2022-06-29
CA3151821A1 (en) 2021-03-04
US20220289759A1 (en) 2022-09-15
KR20220051365A (ko) 2022-04-26
JP7651557B2 (ja) 2025-03-26
BR112022003383A2 (pt) 2022-05-17
JP2022545019A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
CL2021000972A1 (es) Inhibidores de la proteína tirosina fosfatasa
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CL2020000427A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2017000806A (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
AR097388A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
EA201791239A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
MX2019000527A (es) Inhibidores de cinasa dependiente de ciclina 7 (cdk7).
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
EA202092442A2 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX2020013116A (es) Sales y cristales novedosos.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
DOP2014000096A (es) Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PE20211246A1 (es) Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.